NCT06104683View on ClinicalTrials.gov

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 1, 2024

Primary Completion Date

January 16, 2026

Study Completion Date

February 13, 2026

Conditions
Relapsing Multiple SclerosisMultiple Sclerosis
Interventions
DRUG

Placebo

Administered orally

DRUG

Pirtobrutinib

Administered orally

Trial Locations (4)

969

Caribbean Center For Clinical Research Inc, Guaynabo

33612

University of South Florida, Tampa

77074

Clinical Trial Network, Houston

98122-5698

Swedish Medical Center-501 E Hampden Ave, Seattle

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Loxo Oncology, Inc.

INDUSTRY

NCT06104683 - A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis | Biotech Hunter | Biotech Hunter